Repurposing Approved Kinase Inhibitors Could Combat Drug Resistance
PHILADELPHIA (January 14, 2016) – This unprecedentedly large-scale screen revealed lead compounds that are more selective than approved drugs against mutant kinases and therefore less likely to produce resistance or side effects in patients.